Publication | Closed Access

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Chronic PhaseHematological MalignancyChronic Myeloid LeukemiaOncologyMedicineImmunologyHematologyMyeloid NeoplasiaAdult T-cell Leukemia-lymphomaMolecular DiagnosticsRadiation OncologySuperior Molecular ResponsesHealth Sciences